Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;2004(1):CD003885.
doi: 10.1002/14651858.CD003885.pub2.

Pneumococcal vaccines for sickle cell disease

E G Davies  1 , C Riddington, R Lottenberg, N Dower
Affiliations

Pneumococcal vaccines for sickle cell disease

E G Davies et al. Cochrane Database Syst Rev. 2004.

Abstract

Background: People with sickle cell disease are particularly susceptible to pneumococcal infection, which may be fatal. Infants (children aged up to 23 months) are at particularly high risk, but conventional polysaccharide pneumococcal vaccines may be ineffective in this age group. New conjugate pneumococcal vaccines are now available, which may help to reduce the incidence of infection in people with sickle cell disease.

Objectives: To determine the efficacy of pneumococcal vaccines for reducing morbidity and mortality in people with sickle cell disease.

Search strategy: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group trials register, comprising of references identified from comprehensive electronic database searches and hand searching relevant journals and abstract books of conference proceedings. In addition, we contacted relevant pharmaceutical companies and experts in the field.Date of most recent search of Group's trials register: November 2003.

Selection criteria: All randomised and quasi-randomised controlled trials comparing a polysaccharide or conjugate pneumococcal vaccine regimen with a different regimen or no vaccination in people with sickle cell disease.

Data collection and analysis: Two reviewers independently selected studies for inclusion, extracted data and assessed trial quality.

Main results: Nine trials were identified in the searches and five trials, with a total of 547 participants, met the inclusion criteria. Only one trial reported incidence of pneumococcal infection, and this demonstrated that the polysaccharide pneumococcal vaccine used (PPV14) failed to significantly reduce the risk of infection in children under three years of age, but was associated with only minor adverse events. Three trials of conjugate pneumococcal vaccines found that immune response was increased compared to control groups, including in infants, although clinical outcomes were not measured in these trials.

Reviewer's conclusions: Previous trials have shown that conjugate pneumococcal vaccines are safe and effective in normal healthy patients, even those under the age of two years. The controlled trials included in this review have demonstrated immunogenicity (the body's response, without which there is no protection) of these vaccines, and observational studies in people with sickle cell disease support these findings. We therefore recommend that conjugate pneumococcal vaccines are used in people with sickle cell disease. Randomised trials in patients with sickle cell disease will be needed to determine the optimal vaccination regimen when further, potentially more effective vaccines become available. Such trials should measure clinical outcomes of effectiveness.

PubMed Disclaimer

Conflict of interest statement

Since the publication of the original review Graham Davies has been awarded funding by Wyeth Pharmaceuticals to conduct an investigator‐sponsored study of conjugate pneumococcal vaccine in another condition as well as sponsorship to attend an international conference.

Since publication of the original review, Ceri Hirst has received funding from several pharmaceutical companies for contract research unrelated to the review topic.

Figures

1.1
1.1. Analysis
Comparison 1 PPV14 versus Hib, Outcome 1 Incidence of proven pneumococcal infection.
2.1
2.1. Analysis
Comparison 2 PPV14 versus placebo, Outcome 1 Adverse events related to the vaccine.
3.1
3.1. Analysis
Comparison 3 PPV23 versus PCV7+PPV23, Outcome 1 Antibody responses.
3.2
3.2. Analysis
Comparison 3 PPV23 versus PCV7+PPV23, Outcome 2 Adverse events related to the vaccine.
4.1
4.1. Analysis
Comparison 4 PCV9+PPV23 versus Hib+PPV23, Outcome 1 Fatalities.
4.2
4.2. Analysis
Comparison 4 PCV9+PPV23 versus Hib+PPV23, Outcome 2 Antibody responses.
5.1
5.1. Analysis
Comparison 5 PCV9+Hib versus PCV9, Outcome 1 Fatalities.
5.2
5.2. Analysis
Comparison 5 PCV9+Hib versus PCV9, Outcome 2 Antibody responses.
6.1
6.1. Analysis
Comparison 6 PCV9+Hib versus PCV9+PPV23, Outcome 1 Fatalities.
6.2
6.2. Analysis
Comparison 6 PCV9+Hib versus PCV9+PPV23, Outcome 2 Antibody responses.
7.1
7.1. Analysis
Comparison 7 PCV9+PPV23 versus PCV9, Outcome 1 Fatalities.
7.2
7.2. Analysis
Comparison 7 PCV9+PPV23 versus PCV9, Outcome 2 Antibody responses.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD003885

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Goldblatt 2000 {published and unpublished data}
    1. Goldblatt D, Akoto OY, Ashton L, Asafo‐Adjei E, Brainsby K, Twumasi P, et al. Does one dose of pneumococcal conjugate vaccine induce immunological memory in toddlers? [abstract]. Abstracts from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ISAAC). 2000:235 (42a).
Goldblatt 2003a {published and unpublished data}
    1. Goldblatt D, Akota OY, Ashton L, Asafo‐Adjei E, Brainsby K, Twumasi P, et al. Immunogenicity of 9V conjugate vaccines in infants with sickle cell disease. Unpublished.
    1. Goldblatt D, Akoto AY, Ashton L, Asafo‐Adjei E, Brainsby K, Twumasi P, et al. Immunogenicity and the generation of immune memory following 9‐valent penumococcal conjugate vaccination in Ghanaian infants with sickle cell disease [abstract]. Abstracts from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2000:245 (688a).
John 1984 {published data only}
    1. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. British Medical Journal 1984;288(6430):1567‐70. - PMC - PubMed
Rigau‐Perez 1983 {published data only}
    1. Rigau‐Perez JG, Overturf GD, Chan LS, Weiss J, Powars D. Reactions to booster pneumococcal vaccination in patients with sickle cell disease. Pediatric Infectious Disease 1983;2(3):199‐202. - PubMed
Vernacchio 1998 {published data only}
    1. Vernacchio L, Neufeld EJ, MacDonald K, Kurth S, Murakami S, Hohne C, et al. Combined schedule of 7‐valent pneumococcal conjugate vaccine followed by 23‐valent pneumococcal vaccine in children and young adults with sickle cell disease. Journal of Pediatrics 1998;133(2):275‐8. - PubMed
    1. Vernacchio L, Romero‐Steiner S, Martinez JE, MacDonald K, Barnard S, Pilishvili T, et al. Comparison of an opsonophagocytic assay and IgG Elisa to assess repsonses to pneumococcal polysaccharide and pneumococcal conjugate vaccine in children and young adults with sickle cell disease. Journal of Infectious Diseases 2000;181(3):1162‐6. - PubMed

References to studies excluded from this review

Ambrosino 1986 {published data only}
    1. Ambrosino DM, Landesman SH, Gorham CC, Siber GR. Passive immunization against disease due to Haemophilus influenzae Type b: concentrations of antibody to capsular polysaccaride in high‐risk children. Journal of Infectious Diseases 1986;153(1):1‐7. - PubMed
Bjornson 1996 {published data only}
    1. Bjornson AB, Falletta JM, Verter JI, Buchanan GR, Miller ST, Pegelow CH, et al. Serotype‐specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. Journal of Pediatrics 1996;129(6):828‐35. - PubMed
Chintu 1983 {published data only}
    1. Chintu C, Gupta K, Osborne C, Masona JM. Clinical trial of the protective role of polyvalent pneumococcal vaccine in sickle cell anaemia patients in Zambia. Medical Journal of Zambia 1983;17(3):73‐6. - PubMed
Frank 1987 {published data only}
    1. Frank AL, Labotka RJ, Rao S, Frisone LR, McVerry PH, Samuelson JS, et al. Haemophilus influenzae type B immunization of children with sickle cell disease. Pediatrics 1988;82(4):571‐5. - PubMed

Additional references

Adamkiewicz 2003
    1. Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23‐valent pneumococcal polysaccharide vaccination. Journal of Pediatrics 2003;143(4):438‐44. - PubMed
Alpern 2001
    1. Alpern ER, Alessandrini EA, McGowan KL, Bell LM, Shaw KN. Serotype prevalence of occult pneumococcal bacteraemia. Pediatrics 2001;108(2):e23. - PubMed
Ammann 1977
    1. Ammann A, Addiego J, Wara D, Lubin B, Smith W, Mentzer W. Polyvalent pneumococcal‐polysaccharide immunization of patients with sickle‐cell anemia and patients with splenectomy. New England Journal of Medicine 1977;297(17):897‐900. - PubMed
Anderson 1996
    1. Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. Journal of Pediatrics 1996;128(5 (Part 1)):649‐53. - PubMed
Barrett‐Connor 1971
    1. Barrett‐Connor E. Infection and sickle cell‐C disease. The American Journal of Medical Sciences 1971;262(3):162‐9. - PubMed
BCSH 1996
    1. Working Party of the British Committee for Standards in Haematology Clinical Haematology Taskforce. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. BMJ 1996;312(7028):430‐4. - PMC - PubMed
Begg 1994
    1. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088‐101. - PubMed
Bjornson 1981
    1. Bjornson AB, Lobel JS, Magnafici PI, Lampkin BC. Restoration by normal human immunoglobulin G of deficient serum opsonisation for streptococcus pneumoniae in sickle cell disease. Infection and Immunology 1981;33(2):636‐40. - PMC - PubMed
Bjornson 1987
    1. Bjornson AB, Lobel JS. Direct evidence that decreased serum opsonisation of Streptococcus pneumoniae via the alternative pathway in sickle cell disease is related to antibody deficiency. Journal of Clinical Investigation 1987;79(2):388‐98. - PMC - PubMed
Black 2000
    1. Black S, Shinefield H, Fireman B, Lewis P, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of hepavalent pneumococcal conjugated vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infectious Disease Journal 2000;19(3):187‐95. - PubMed
Breukels 2001
    1. Breukels MA, Zandvoort A, Dobbelsteen GP, Muijsenberg A, Lodewijk ME, Beurret M, et al. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides. Infection and Immunity 2001;69(12):7583‐7. - PMC - PubMed
Buchanan 1983
    1. Buchanan GR, Smith SJ, Holtkamp CA, Fuseler JP. Bacterial infection and splenic reticuloendothelial function in children with haemoglobin SC disease. Pediatrics 1983;72(1):93‐8. - PubMed
CDC 1997
    1. Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in Streptococcus pneumoniae‐selected sites, United States. Morbidity and Mortality Weekly Report 1997;48:656‐61. - PubMed
CDC 2000
    1. Center for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children . Recommendations of the Advisory Committee on Immunisation Practices. Morbidity and Mortality Weekly Report 2000;49:1‐35. - PubMed
Clarke 2001
    1. Clarke M, Oxman AD, editors. Assesssment of Study Quality. Selection bias. Cochrane Reviewers' Handbook 4.1.4 [updated October 2001]; Section 6.3. In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Oxford: Update Software; 2002, Issue 4.
CMO 2002
    1. Chief Medical Officer UK. Pneumococcal conjugate vaccine for children under two years of age. http://ww.doh.gov.uk/cmo/letters/cmo0204.htm accessed 25/04/2003.
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31:140‐9. - PubMed
Eskola 2001
    1. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. New England Journal of Medicine 2001;344(6):403‐9. - PubMed
Finn 2002
    1. Finn A, Booy R, Moxon R, Sharland M, Heath P. Should the new pneumococcal vaccine be used in high‐risk children?. Achives of Disease in Childhood 2002;87(1):18‐21. - PMC - PubMed
Flint 1993
    1. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of haemoglobinopathies. Balliere's Clinical Haemotology 1993;6(1):215‐62. - PubMed
Gill 1995
    1. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue R, Grover R, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995;86(2):776‐83. - PubMed
Goldblatt 2003b
    1. Goldblatt D. Personal communication October 2003.
Gordon 2003
    1. Gordon SB, Kanyanda S, Walsh AL, Goddard K, Chaponda M, Atkinson V, et al. Poor potential coverage for 7‐valent pneumococcal conjugate vaccine, Malawi. Emerging Infectious Disease 2003;9(6):747‐749. - PMC - PubMed
Hedges 1985
    1. Hedges LV, Olkin I. Statistical Methods for Meta‐Analysis. Toronto: Academic Press, 1985.
Hudspeth 2001
    1. Hudspeth MK, Smith TC, Barrozo CP, Hawksworth AW, Ryan MA, Gray GC, Streptococcus pneumoniae Surveillance Group. National Department of Defence Surveillance for Invasive Streptococcus pneumoniae: antibiotic resistance, serotype distribution and arbitrarily primed polymerase chain reaction analyses. The Journal of Infectious Diseases 2001;184(5):591‐6. - PubMed
JCVI 2004
    1. Joint Committee on Vaccination and Immunisation. JCVI Annual Report 2004. http://www.advisorybodies.doh.gov.uk/JCVI/annualreports.htm.
Johnston 1973
    1. Johnston RB Jr, Newman SL, Struth AG. An abnormality of the alternate pathway of complement activation in sickle‐cell disease. New England Journal of Medicine 1973;288(16):803‐8. - PubMed
Joloba 2001
    1. Joloba ML, Bajaksouzian S, Palavecino E, Whalen C, Jacobs MR. High prevalence of carriage of antibiotic resistant Streptococcus pneumoniae in children in Kampala Uganda. International Journal of Antimicrobial Agents 2001;17(5):395‐400. - PubMed
Kaplan 1982
    1. Kaplan J, Frost H, Sarnaik S, Schiffman G. Type‐specific antibodies in children with sickle cell anemia given polyvalent pneumococcal vaccine. Journal of Pediatrics 1982;100(3):404‐6. - PubMed
Klugman 2003
    1. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, et al. A trial of 9‐valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England Journal of Medicine 2003;349(14):1341‐8. - PubMed
Kyaw 2000
    1. Kyaw MH, Clarke S, Edwards GF, Jones IG, Campbell H. Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies. Epidemiology and Infection 2000;125(3):561‐72. - PMC - PubMed
Nowak 2000
    1. Nowak‐Wegrzyn A, Winkelstein JA, Swift AJ, Lederman HM, The Pneumococcal Conjugate Vaccine Study Group. Serum opsonic activity in infants with sickle cell disease immunized with pneumococcal polysaccharide protein conjugate vaccine. Clinical and Diagnostic Laboratory Immunology 2000;7(5):788‐93. - PMC - PubMed
O'Brien 2000
    1. O'Brien KL, Swift AJ, Winkelstein JA, Santosham M, Stover B, Luddy R, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pediatrics 2000;106(5):965‐72. - PubMed
O'Brien 2003
    1. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of 7‐valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. The Lancet 2003;362(9381):355‐361. - PubMed
Overturf 1982
    1. Overturf GD, Selzer JW, Chan L, Weiss J, Field R, Rigau‐Perez JG, et al. Pneumococcal polysaccharide immunisation of children with sickle cell disease. II. Serological response and pneumococcal disease following immunisation. American Journal of Pediatric Hematology/Oncology 1982;4(1):25‐35. - PubMed
Pearson 1985
    1. Pearson HA, Gallagher D, Chilcote R, Sullivan E, Wilimas J, Espeland M, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985;76(3):392‐7. - PubMed
Pelton 2000
    1. Pelton SI. Acute otitis media in the era of effective pneumococcal conjugate vaccine: will new pathogens emerge?. Vaccine 2000;19(Suppl 1):S96‐9. - PubMed
Pelton 2002
    1. Pelton SI, Klein JO. The future of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in infants and children. Pediatrics 2002;110(4):805‐14. - PubMed
RCPCH 2002
    1. Royal College of Pediatrics and Child Health. Immunisation of the immunocompromised child. http://www.rcpch.ac.uk/publications/recent_publications/Immunocomp.pdf accessed 25/04/2003.
Reacher 2000
    1. Reacher MH, Shah A, Livermore DM, Wale M, Graham C, Johnson AP, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000;320(7229):213‐6. - PMC - PubMed
Robinson 2001
    1. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995‐1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001;285(13):1729‐35. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Sleeman 2001
    1. Sleeman K, Knox K, George R, Miller E, Waight P, Griffiths D, et al. Invasive pneumococcal disease in England and Wales: vaccination implications. Journal of infectious Diseases 2001;183(2):239‐46. - PubMed
Steele 1996
    1. Steele RW, Warrier R, Unkel PJ, Foch BJ, Howes RF, Shah S, et al. Colonization with antibiotic‐resistant Streptococcus pneumoniae in children with sickle cell disease. Journal of Pediatrics 1996;128(4):531‐5. - PubMed
Vergnaud 2001
    1. Vergnaud M, Laaberki MF. Pneumococcal antibiotic resistance. Results from 21 regional registries for 1999 [Resistance du pneumocoque aux antibiotiques. Resultats de 21 observatoires regionaux pour l'annee 1999]. Presse Medicale 2001;Spec No 1:7‐10. - PubMed
Winkelstein 1968
    1. Winkelstein JA, Drachman RH. Deficiency of pneumococcal serum opsonizing activity in sickle cell disease. New England Journal of Medicine 1968;279(9):459‐66. - PubMed
Wise 2004
    1. Wise RP, Iskander J, Pratt RD, Campbell S, Ball R, Pless RP, et al. Postlicensure safety surveillance for 7‐valent pneumococcal conjugate vaccine. JAMA 2004;292(14):1702‐10. - PubMed
Wolf 1999
    1. Wolf HM, Eibl MM, Georgi E, Samstag A, Spatz M, Uranus S, et al. Long ‐term decrease of CD4+ CD45RA+ T cells and impaired primary immune response after post ‐traumatic splenectomy. British Journal of Haematology 1999;107(1):55‐68. - PubMed
Zarkowsky 1986
    1. Zarkowsky HS, Gallagher D, Gill FM, Wang WC, Falletta JM, Lande WM, et al. Bacteremia in sickle hemoglobinopathies. Journal of Pediatrics 1986;109(4):579‐85. - PubMed

Publication types

MeSH terms

LinkOut - more resources